Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v20.i5-6.120
pages 407-417

Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer

Justin Q. Wang
Department of Medicine, Rhode Island Hospital, Providence, RI
Austin DeChalus
Department of Medicine, Rhode Island Hospital, Providence, RI
Devin N. Chatterjee
Department of Medicine, Rhode Island Hospital, Providence, RI
Evan T. Keller
Department of Urology, School of Medicine, University of Michigan, 1500 E. Medical Center Dr., Room 5308 CCGCB, Ann Arbor, MI 48105, USA; Center for Translational Medicine, Guangxi Medical University, Nanning, China
Atsushi Mizokami
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan
Giovanni Camussi
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
Andrew R. Mendelsohn
Regenerative Sciences Institute, 1230 Bordeaux Dr., Sunnyvale, CA
Joseph F. Renzulli II
Department of Urology, Miriam Hospital, The Alpert Medical School of Brown University, Providence, RI
Peter J. Quesenberry
Department of Medicine, Rhode Island Hospital, Providence, RI
Devasis Chatterjee
Rhode Island Hospital and The Alpert Medical School of Brown University, Providence, Rhode Island

ABSTRACT

Prostate cancer (PCa) is the most common solid tumor in males and the second leading cause of cancer-related deaths in males in the United States. The current first line therapy for metastatic PCa is androgen deprivation therapy and is initially effective against the disease. However, castrate resistant prostate cancer (CRPC) develops in many men within 18−36 months, rendering this treatment ineffective. Chemotherapy, with a class of drugs known as taxanes is the standard-of-care cytotoxic option in metastatic castrate resistant PCa (mCRPC). However, the overall survival advantage for chemotherapy in mCRPC is only 2.2 months and the cancer cells often become resistant to these drugs as well. Once patients fail chemotherapy the progression to death is inevitable. Extracellular vesicles (EVs) are involved in cell signaling and play a role in cancer progression. Previous work has demonstrated that EVs are involved in the development of drug resistance in cancer cells. We report the reversal of taxane resistance and tumorigenic phenotype in PCa cells after EVs treatment. This study suggests that EVs represent a potentially novel therapeutic treatment option for CRPC.